Orchard Therapeutics PLC (ORTX)

NASDAQ: ORTX · IEX Real-Time Price · USD
1.01
-0.06 (-5.61%)
At close: Jan 21, 2022 4:00 PM
1.02
0.01 (0.99%)
After-hours:Jan 21, 2022 6:48 PM EST
Market Cap126.75M
Revenue (ttm)1.19M
Net Income (ttm)-141.86M
Shares Out125.50M
EPS (ttm)-1.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume932,964
Open1.07
Previous Close1.07
Day's Range0.98 - 1.08
52-Week Range0.98 - 9.08
Beta1.11
AnalystsStrong Buy
Price Target10.31 (+921.0%)
Earnings Daten/a

About ORTX

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinica...

IndustryBiotechnology
IPO DateOct 31, 2018
Employees224
Stock ExchangeNASDAQ
Ticker SymbolORTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ORTX stock is "Strong Buy." The 12-month stock price forecast is 10.31, which is an increase of 921.04% from the latest price.

Price Target
$10.31
(921.04% upside)
Analyst Consensus: Strong Buy

News

Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatme...

Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients

2 days ago - GlobeNewsWire

Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and...

Launch Momentum Building for Libmeldy® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients

1 week ago - GlobeNewsWire

Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the virtual 40th Annua...

2 weeks ago - GlobeNewsWire

Top Penny Stocks to Buy Under $3? Check These 3 Out

Are these $3 penny stocks worth buying in 2022? The post Top Penny Stocks to Buy Under $3?

Other symbols:CPOPSEAC
3 weeks ago - PennyStocks

Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results ...

100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy

2 months ago - GlobeNewsWire

Orchard Therapeutics to Present at Virtual Investor Conferences in November 2021

BOSTON and LONDON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be available ...

2 months ago - GlobeNewsWire

Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates

Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy in Multiple Neurodegenerative Disorders

2 months ago - GlobeNewsWire

Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress

Nine accepted abstracts demonstrate broad potential of the company's HSC gene therapy approach to treat severe neurodegenerative diseases and immunological disorders Nine accepted abstracts demonstrate ...

3 months ago - GlobeNewsWire

Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future ...

Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed

4 months ago - GlobeNewsWire

Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments

Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively

4 months ago - GlobeNewsWire

Orchard Therapeutics to Host Virtual R&D Investor Event on Tuesday, September 14, 2021

BOSTON and LONDON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D Investor Event on Tue...

4 months ago - GlobeNewsWire

Orchard Therapeutics Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

BOSTON and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Compensation Committee of Orchard's Board of Directors a...

4 months ago - GlobeNewsWire

Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates

Regulatory feedback obtained on OTL-200 (MLD) and OTL-203 (MPS-IH) programs

5 months ago - GlobeNewsWire

Orchard Therapeutics, Pharming Ink Development Pact For Gene Therapy

Orchard Therapeutics plc (NASDAQ: ORTX) and Pharming Group NV (NASDAQ: PHAR) have collaborated to research, develop, manufacture and commercialize OTL-105 for hereditary angioedema (HAE). OTL-105 is an ...

6 months ago - Benzinga

Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Ge...

Highlights the broader potential of Orchard's ex vivo HSC gene therapy platform approach in new and larger indications

6 months ago - GlobeNewsWire

Orchard Therapeutics Issues Updates On Gene Therapy Programs

Orchard Therapeutics plc (NASDAQ: ORTX) has provided updates on the progress of its lead gene therapy programs targeting metachromatic leukodystrophy (MLD), mucopolysaccharidosis type I Hurler syndrome ...

6 months ago - Benzinga

Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs

Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA

6 months ago - GlobeNewsWire

Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates

Commercial Activities Advancing for Upcoming Launch of Libmeldy TM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany

8 months ago - GlobeNewsWire

Orchard Therapeutics Posts Long-Term Data For Gene Therapy In Inherited Immune System Disorder

Three years after receiving gene therapy from Orchard Therapeutics (NASDAQ: ORTX) in an early-stage clinical trial, 100% of patients with an inherited disease that damages the immune system were still a...

8 months ago - Benzinga

Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID

100% overall survival and ≥ 95% event-free survival observed at two and three years following one-time treatment with lentiviral HSC gene therapy

8 months ago - GlobeNewsWire

Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Ce...

Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders

8 months ago - GlobeNewsWire

Regenerative Medicine Attracted Record $20 Billion in Funding in 2020

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

10 months ago - GuruFocus

Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support ...

MINNEAPOLIS--(BUSINESS WIRE)--Be The Match BioTherapies announced an expansion of their multi-year partnership with Orchard Therapeutics.

10 months ago - Business Wire

Recap: Orchard Therapeutics Q4 Earnings

Shares of Orchard Therapeutics (NASDAQ:ORTX) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 26.09% year over year to ($0.34), which beat the esti...

10 months ago - Benzinga

Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments

$150M Strategic Financing Supports Execution into the First Half of 2023

10 months ago - GlobeNewsWire